Lonza(LZAGY) - 2022 Q2 - Earnings Call Presentation

Financial Performance - Lonza Group achieved solid H1 performance with sales of CHF 3 billion and a CER growth of 16.8%[6], resulting in a CORE EBITDA of CHF 987 million and a margin of 33.1%[6] - The Biologics division experienced strong growth, with sales increasing by 26.2% CER[24], while the Small Molecules division saw a decrease in sales of 21.3% CER due to phasing of customer deliveries[24] - Capsules & Health Ingredients division achieved a sales growth of 4.0% CER and a CORE EBITDA margin of 35.2%[24] - H1 2022 CAPEX was reported at 28.2% of sales[13] Investments and Strategy - Lonza announced an investment of approximately CHF 500 million in Fill & Finish to build a large-scale commercial drug product facility, expected to be completed in 2026[6, 10] - The company is delivering CAPEX projects to support long-term growth, with investments across divisions to expand capabilities[11, 13] - Over 80% of investments are to support growth, with a total project portfolio of CHF 841 million in H1 2022[28] Outlook and Priorities - Lonza confirmed its Group Outlook 2022, projecting low to mid-teens CER sales growth and CORE EBITDA margin improvement[6] - The company is focused on delivering CAPEX investment projects, meeting financial targets through operational excellence, and maintaining focus on innovation and differentiation[8] - Lonza continues to advance its ESG agenda, incorporating ESG targets into employee and executive remuneration policy[8, 14]